×
Log in
Get Started
Travel
Technology
Sports
Marketing
Education
Career
Social Media
+ Explore all categories
Report -
Neue Substanzklassen in der Onkologie (Tyrosin)Kinase ...€¦ · Vemurafenib (Zelboraf®) BRAF-Inhibitor Zulassung für fortgeschrittenes malignes Melanom OS nach 6 Monaten: 84%
Select
Pornographic
Defamatory
Illegal/Unlawful
Spam
Other Terms Of Service Violation
File a copyright complaint
Please pass captcha verification before submit form
